
Opinion|Videos|April 2, 2025
Overcoming Barriers to Treatment in AD
Author(s)Matthew Zirwas, M.D.
An expert discusses the most common barriers clinicians face when prescribing topical therapies for atopic dermatitis (AD) and their impact on patient adherence as well as strategies dermatologists can employ to navigate insurance coverage, prior authorization and step therapy to ensure patients receive appropriate care.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the most common barriers clinicians face when prescribing topical therapies for AD, and how do they impact patient adherence?
- What strategies can dermatologists employ to navigate insurance coverage, prior authorization and step therapy, and ensure patients receive appropriate care?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first treatment for chronic hepatitis D virus
2
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
3
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
4
Recent COVID vaccination cuts household transmission by half
5





















